87 related articles for article (PubMed ID: 1843183)
1. Acute toxic effects of sustained-release verapamil in chronic renal failure.
Pritza DR; Bierman MH; Hammeke MD
Arch Intern Med; 1991 Oct; 151(10):2081-4. PubMed ID: 1843183
[TBL] [Abstract][Full Text] [Related]
2. Junctional bradycardia with verapamil in renal failure--care required even with mild hyperkalaemia.
Hegazi MO; Aldabie G; Al-Mutairi S; El Sayed A
J Clin Pharm Ther; 2012 Dec; 37(6):726-8. PubMed ID: 22568727
[TBL] [Abstract][Full Text] [Related]
3. Verapamil deleterious effects in chronic renal failure.
Váquez C; Huelmos A; Alegría E; Errasti P; Purroy A
Nephron; 1996; 72(3):461-4. PubMed ID: 8852497
[TBL] [Abstract][Full Text] [Related]
4. Massive overdose of sustained-release verapamil: a case report and review of literature.
Ashraf M; Chaudhary K; Nelson J; Thompson W
Am J Med Sci; 1995 Dec; 310(6):258-63. PubMed ID: 7503108
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy comparison of immediate-release and sustained-release oral verapamil in systemic hypertension.
Frishman WH; Eisen G; Charlap S; Strom JA
J Clin Hypertens; 1987 Dec; 3(4):605-9. PubMed ID: 3134517
[TBL] [Abstract][Full Text] [Related]
6. Verapamil and mild hyperkalemia in hemodialysis patients: a potentially hazardous association.
Letavernier E; Couzi L; Delmas Y; Moreau K; Murcott O; de Précigout V
Hemodial Int; 2006 Apr; 10(2):170-2. PubMed ID: 16623670
[TBL] [Abstract][Full Text] [Related]
7. [Toxic effects of verapamil in chronic renal failure].
Tomás S; Duaso E; Llibre J
Med Clin (Barc); 1994 Apr; 102(12):478. PubMed ID: 8208003
[No Abstract] [Full Text] [Related]
8. Efficacy and tolerability of enalapril and sustained-release verapamil in older patients with mild to moderate essential hypertension.
Weir MR; Cassidy CA; Hall PS; Lancaster A; Schubert C; Urick A; Saunders E; Kong BW; Jenkins P; Lavin PT
Clin Ther; 1990; 12(2):139-48. PubMed ID: 2354483
[TBL] [Abstract][Full Text] [Related]
9. Safety of controlled-onset extended-release verapamil in middle-aged and older patients with hypertension and coronary artery disease.
White WB; Johnson MF; Anders RJ; Elliott WJ; Black HR
Am Heart J; 2001 Dec; 142(6):1010-5. PubMed ID: 11717605
[TBL] [Abstract][Full Text] [Related]
10. [Sustained release verapamil in essential hypertension].
Yodfat Y; Nusbaum M; Gibor Y
Harefuah; 1991 May; 120(10):581-4. PubMed ID: 1937192
[TBL] [Abstract][Full Text] [Related]
11. [The toxicity of slow-release verapamil and chronic kidney disease].
Huelmos A; Alegría E; Vázquez C
Rev Esp Cardiol; 1994 Nov; 47(11):780. PubMed ID: 7800911
[No Abstract] [Full Text] [Related]
12. Conversion from sustained-release to immediate-release calcium entry blockers: outcome in patients with mild-to-moderate hypertension.
Hilleman DE; Mohiuddin SM; Lucas BD; Shinn B; Elsasser GN
Clin Ther; 1993; 15(6):1002-10. PubMed ID: 8111798
[TBL] [Abstract][Full Text] [Related]
13. Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking.
Kang D; Verotta D; Krecic-Shepard ME; Modi NB; Gupta SK; Schwartz JB
Clin Pharmacol Ther; 2003 Jan; 73(1):31-40. PubMed ID: 12545141
[TBL] [Abstract][Full Text] [Related]
14. Long term effects of sustained release verapamil on the renal and systemic haemodynamic parameters in hypertensive patients with mild to severe chronic renal failure.
Schohn DC; Jahn HA; Maareck M
Drugs; 1993; 46 Suppl 2():113-9; discussion 119-20. PubMed ID: 7512464
[TBL] [Abstract][Full Text] [Related]
15. Verapamil sustained-release in renal parenchymal hypertension: effect on blood pressure, kidney function, angiotensin II, aldosterone, arginine vasopressin, atrial natriuretic peptide, and lipoproteins.
Eiskjaer H; Pedersen EB; Rasmussen LM; Jespersen B
J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S17-22. PubMed ID: 2475677
[TBL] [Abstract][Full Text] [Related]
16. Effect of light exercise on renal hemodynamics in patients with hypertension and chronic renal disease.
Svarstad E; Myking O; Ofstad J; Iversen BM
Scand J Urol Nephrol; 2002; 36(6):464-72. PubMed ID: 12623513
[TBL] [Abstract][Full Text] [Related]
17. A new sustained-release formulation of verapamil in the treatment of hypertension.
Midtbo KA; Hals O; Lauve O
J Clin Hypertens; 1986 Sep; 2(3 Suppl):125S-132S. PubMed ID: 3540222
[TBL] [Abstract][Full Text] [Related]
18. [Kidney function in hypertensive patients with chronic renal failure treated with the dual eliminated ACE-inhibitor spirapril].
Haufe CC; Sierakowski B; Jansa U; Stein G
Med Klin (Munich); 1994 Aug; 89(8):416-20. PubMed ID: 7968874
[TBL] [Abstract][Full Text] [Related]
19. [Delayed-release verapamil hydrochloride in chronic atrial fibrillation. Reducing the heart rate].
Gonska BD; Wiedey KD
Fortschr Med; 1990 Sep; 108(27):521-4. PubMed ID: 2227752
[TBL] [Abstract][Full Text] [Related]
20. Verapamil versus nifedipine in slow-release preparations for the treatment of mild to moderate hypertension.
Shamiss A; Meisel S; Nussinovitch N; Rosenthal T
J Hum Hypertens; 1990 Aug; 4(4):465-8. PubMed ID: 2258895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
